Evidence of Prognostic Relevant Expression Profiles of Heat-Shock Proteins and Glucose-Regulated Proteins in Oesophageal Adenocarcinomas

A high percentage of oesophageal adenocarcinomas show an aggressive clinical behaviour with a significant resistance to chemotherapy. Heat-shock proteins (HSPs) and glucose-regulated proteins (GRPs) are molecular chaperones that play an important role in tumour biology. Recently, novel therapeutic approaches targeting HSP90/GRP94 have been introduced for treating cancer. We performed a comprehensive investigation of HSP and GRP expression including HSP27, phosphorylated (p)-HSP27(Ser15), p-HSP27(Ser78), p-HSP27(Ser82), HSP60, HSP70, HSP90, GRP78 and GRP94 in 92 primary resected oesophageal adenocarcinomas by using reverse phase protein arrays (RPPA), immunohistochemistry (IHC) and real-time quantitative RT-PCR (qPCR). Results were correlated with pathologic features and survival. HSP/GRP protein and mRNA expression was detected in all tumours at various levels. Unsupervised hierarchical clustering showed two distinct groups of tumours with specific protein expression patterns: The hallmark of the first group was a high expression of p-HSP27(Ser15, Ser78, Ser82) and low expression of GRP78, GRP94 and HSP60. The second group showed the inverse pattern with low p-HSP27 and high GRP78, GRP94 and HSP60 expression. The clinical outcome for patients from the first group was significantly improved compared to patients from the second group, both in univariate analysis (p = 0.015) and multivariate analysis (p = 0.029). Interestingly, these two groups could not be distinguished by immunohistochemistry or qPCR analysis. In summary, two distinct and prognostic relevant HSP/GRP protein expression patterns in adenocarcinomas of the oesophagus were detected by RPPA. Our approach may be helpful for identifying candidates for specific HSP/GRP-targeted therapies.

[1]  Helen M. Moore,et al.  Biospecimen Reporting for Improved Study Quality (BRISQ) , 2013, Transfusion.

[2]  C. Garrido,et al.  Targeting heat shock proteins in cancer. , 2013, Cancer letters.

[3]  Michael Riffle,et al.  A Mass Spectrometry Proteomics Data Management Platform* , 2012, Molecular & Cellular Proteomics.

[4]  R. Langer,et al.  High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer , 2012, Cellular Oncology.

[5]  S. Deraz,et al.  Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? , 2011, Biochimica et biophysica acta.

[6]  G. Murray,et al.  The Proteomics of Colorectal Cancer: Identification of a Protein Signature Associated with Prognosis , 2011, PloS one.

[7]  R. Hendrickson,et al.  Identification of Direct Target Engagement Biomarkers for Kinase-Targeted Therapeutics , 2011, PloS one.

[8]  R. Langer,et al.  Discovery of New Molecular Subtypes in Oesophageal Adenocarcinoma , 2011, PloS one.

[9]  K. Coombes,et al.  Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer , 2011, Clinical Proteomics.

[10]  K. Janda,et al.  Inducing apoptosis in chemotherapy‐resistant B‐lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti‐apoptotic unfolded protein response signalling network , 2011, British journal of haematology.

[11]  R. Klopfleisch,et al.  Excavation of a buried treasure--DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. , 2011, Histology and histopathology.

[12]  R. Langer,et al.  Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas: A Summary of 480 Cases , 2011, Annals of surgery.

[13]  Helen M. Moore,et al.  Biospecimen Reporting for Improved Study Quality. , 2011, Biopreservation and biobanking.

[14]  H. Matsubara,et al.  Correlation Between gp96 Expression and the Surgical Outcome in Patients With Esophageal Squamous Cell Carcinoma , 2011, Annals of Surgical Oncology.

[15]  E. Benarroch Heat shock proteins , 2011, Neurology.

[16]  K. Becker,et al.  Successful Protein Extraction from Over-Fixed and Long-Term Stored Formalin-Fixed Tissues , 2011, PloS one.

[17]  H. Höfler,et al.  Signalling networks associated with urokinase‐type plasminogen activator (uPA) and its inhibitor PAI‐1 in breast cancer tissues: new insights from protein microarray analysis , 2011, The Journal of pathology.

[18]  J. Edwards,et al.  GRP78 up‐regulation is associated with androgen receptor status, Hsp70–Hsp90 client proteins and castrate‐resistant prostate cancer , 2011, The Journal of pathology.

[19]  K. Coombes,et al.  Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  G. Chiosis,et al.  The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1 , 2010, Journal of hematology & oncology.

[21]  H. Grabsch,et al.  Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer , 2010, Gut.

[22]  Caterina Barillari,et al.  Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone? , 2010, Cell cycle.

[23]  C. Hunt,et al.  Geldanamycin and its anti-cancer activities. , 2010, Cancer letters.

[24]  Xiaoping Wang,et al.  Correlation between Clinicopathology and Expression of Heat Shock Protein 72 and Glycoprotein 96 in Human Esophageal Squamous Cell Carcinoma , 2010, Clinical & developmental immunology.

[25]  R. Langer,et al.  Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas , 2009, Modern Pathology.

[26]  P. Workman,et al.  Death by chaperone: HSP90, HSP70 or both? , 2009, Cell cycle.

[27]  M. Bergqvist,et al.  Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin , 2009, British Journal of Cancer.

[28]  U. Banerji,et al.  Heat Shock Protein 90 as a Drug Target: Some Like It Hot , 2009, Clinical Cancer Research.

[29]  R. Langer,et al.  Protein Expression Profiling in Esophageal Adenocarcinoma Patients Indicates Association of Heat-Shock Protein 27 Expression and Chemotherapy Response , 2008, Clinical Cancer Research.

[30]  M. Bergqvist,et al.  154 POSTER Hsp90 is expressed and represents a novel target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxy- geldanamycin , 2008 .

[31]  Helen M. Moore,et al.  Documenting biospecimen conditions in reports of studies. , 2008, JAMA.

[32]  R. Langer,et al.  Expression and clinical significance of Glucose Regulated Proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus , 2008, BMC Cancer.

[33]  L. Freitag,et al.  Patient survival by Hsp70 membrane phenotype , 2007, Cancer.

[34]  Amy S. Lee GRP78 induction in cancer: therapeutic and prognostic implications. , 2007, Cancer research.

[35]  D. Parmar,et al.  Proteomics in clinical interventions: achievements and limitations in biomarker development. , 2007, Life sciences.

[36]  J. Nährig,et al.  Quantitative protein analysis from formalin‐fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis , 2007, The Journal of pathology.

[37]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[38]  J. Reitsma,et al.  Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[40]  Amy S. Lee,et al.  Glucose regulated proteins in cancer progression, Drug resistance and immunotherapy , 2006, Cancer biology & therapy.

[41]  C. Gulmann,et al.  Array‐based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer , 2006, The Journal of pathology.

[42]  D. Sawyer,et al.  Heat shock proteins in cancer: chaperones of tumorigenesis. , 2006, Trends in biochemical sciences.

[43]  S. Baldus,et al.  Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer: Implications for Response Classification , 2005, Annals of surgery.

[44]  Seung-Oe Lim,et al.  Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. , 2005, World journal of gastroenterology.

[45]  F. Lordick,et al.  Neoadjuvant therapy for oesophagogastric cancer , 2004, The British journal of surgery.

[46]  H. Höfler,et al.  Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. , 2001, The American journal of pathology.

[47]  H. Höfler,et al.  Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility , 1999, Oncogene.

[48]  Johannes Buchner,et al.  Regulation of Hsp27 Oligomerization, Chaperone Function, and Protective Activity against Oxidative Stress/Tumor Necrosis Factor α by Phosphorylation* , 1999, The Journal of Biological Chemistry.

[49]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  K. Becker,et al.  Producing reverse phase protein microarrays from formalin-fixed tissues. , 2011, Methods in molecular biology.

[51]  K. Becker,et al.  Use of formalin-fixed and paraffin-embedded tissues for diagnosis and therapy in routine clinical settings. , 2011, Methods in molecular biology.

[52]  Daniela Berg,et al.  Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. , 2010, European journal of cancer.

[53]  S. Nishizuka,et al.  Reverse-phase protein lysate microarrays for cell signaling analysis , 2008, Nature Protocols.

[54]  S. DeMeester Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment , 2006, Annals of Surgical Oncology.

[55]  Stuart K. Calderwood,et al.  Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications , 2005, Cell stress & chaperones.

[56]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.